Pure Ductal Carcinoma in Situ: Clinicopathological Experience from a Single Tertiary Care Center

Purpose: In this study, we aimed to assess the clinicopathological characteristics and treatment outcomes of pure Ductal Carcinoma In Situ (DCIS) at XXX, in order to better understand its presentation, treatment approaches and rates of recurrence and progression. Methods: We conducted a retrospective analysis of 50 female patients diagnosed with pure DCIS from 2010 to 2020. Data on demographics, DCIS characteristics, treatment and outcomes were collected. Statistical analysis involved frequency distribution and descriptive statistics. Results: The median age at diagnosis for pure DCIS was 54 years. The median DCIS size was 16 mm and the most common morphological pattern was solid (26%). Grade II was the most frequent nuclear grade (40%), followed by grade III at 34% and grade I at 26%. Central (comedo) necrosis was present in 52% of cases. Regarding hormonal receptor status, 58% of cases were estrogen receptor positive and 44% progesterone receptor positive. Of the 23 cases tested for human epidermal growth factor receptor 2, 20% had positive results and 26% negative results. Negative surgical margins were achieved in 88% of cases. Adjuvant treatment included radiotherapy in 22% of patients and hormonal therapy in 34%. On follow-up, one recurrence and one progression to invasive ductal carcinoma were observed, with no DCIS-related mortality recorded. Conclusion: The findings show a low recurrence/progression rate for pure DCIS, consistent with global data indicating that many cases follow an indolent course. The study underscores the need for individualized treatment strategies to balance prevention of progression and avoidance of overtreatment.